Fast Induced Remodeling in Heart Failure With Preserved Ejection Fraction

Running, not enrolling · Not applicable

Conditions studied: Heart Failure With Preserved Ejection Fraction, Concentric Hypertrophy

In brief

FIRE-HFpEF is a multi-center, prospective, randomized, single-blinded, clinical feasibility study. This study will enroll up to 105 subjects with heart failure with preserved ejection fraction in the United States. Data will be collected to evaluate whether pacing therapies can lead to improvements in exercise capacity and health status of subjects.

Key facts

Study ID

NCT05839730

Run by

Medtronic Cardiac Rhythm and Heart Failure

People needed

105

Starts

2024-09-11

Expected to finish

2027-10-01

Last updated by the study team

2026-08-03

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Diagnosis of Heart Failure, Left Ventricular Ejection Fraction (LVEF) ≥ 55% (this and other measurements must be made within the last year).
• New York Heart Association (NYHA) Functional Class I-III
• Stable on guideline-directed medical therapy (GDMT) heart failure medications as determined by the investigator, for at least 1 month, with the exception of loop diuretic therapy. GDMT should be in accordance with current American Heart Association (AHA)/American College of Cardiology (ACC)/Heart Failure Society of America (HFSA) Guidelines and include consideration of Sodium/glucose cotransporter-2 inhibitors (SGLT2i) therapy.
• V End Diastolic Volume indexed to body surface area (BSA) ≤ 80 mL/m\^2.
• Concentric remodeling or concentric hypertrophy defined as at least one of the following criteria:
• Left ventricular (LV) posterior or lateral wall thickness > 11mm
• Relative wall thickness (RWT) > 0.42
• Male and LV mass indexed to BSA ≥115 g/m2
• Male and LV mass indexed to height ≥ 49.2 g/m2.7
• Female and LV mass indexed to BSA ≥ 95 g/m2
• Female and LV mass indexed to height ≥ 46.7 g/m2.7

You may not qualify if…

• Unable or unwilling to undergo contrast MRI.
• Class I indication for permanent pacing, except for symptomatic chronotropic incompetence
• Current permanent or persistent Atrial fibrillation (A-fib)
• Structural heart disease requiring intervention
• Aortic valve replacement procedure less than 12 months prior to enrollment
• Known pericardial constriction, genetic hypertrophic cardiomyopathy, or infiltrative cardiomyopathy
• Severe aortic or mitral valve disease, defined as severe regurgitation or a valve area < 1cm\^2
• Exertional angina
• Severe pulmonary disease including severe Chronic obstructive pulmonary disease (COPD) (i.e., requiring home oxygen, chronic nebulizer therapy, or chronic oral steroid therapy or hospitalized for pulmonary decompensation within 12 months)
• Estimated glomerular filtration rate (eGFR) < 25 ml/min/1.73m\^2 as calculated by the Modification in Diet in Renal Disease (MDRD) formula
• Uncontrolled blood pressure, defined as systolic pressure outside the range of 100 to 160 mmHg despite anti-hypertensive medication.

Where it is running

• NCH Heart Institute — Naples, Florida, United States
• Prairie Education and Research Cooperative-St. Elizabeth's — O'Fallon, Illinois, United States
• Prairie Education and Research Cooperative-St. John's — Springfield, Illinois, United States
• University of Kansas Medical Center — Kansas City, Kansas, United States
• Duke University — Durham, North Carolina, United States
• Oklahoma Heart Hospital — Oklahoma City, Oklahoma, United States
• Houston Methodist Research Institute — Houston, Texas, United States
• The University of Vermont Medical Center — Burlington, Vermont, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.